Article Sidebar
Views PDF: 4
A case report: catecholamine-secreting adrenal tumor-inducing cardiomyopathy
Main Article Content
Abstract
Introduction: Catecholamine-secreting adrenal tumors (pheochromocytoma/paraganglioma) are rare neoplasms causing paroxysmal hypertension, metabolic disturbances, and cardiomyopathy. Diagnosis relies on biochemical tests (plasma-free metanephrines) and imaging (CT/MRI). Definitive treatment involves tumor resection with perioperative hemodynamic control.
Case summary: A 47-year-old female with no prior hypertension presented with chest pain, hypertensive crisis (180/100 mmHg), hyperglycemia, and metabolic acidosis. Elevated norepinephrine (312.33 pg/mL) and abdominal MRI confirmed a right adrenal tumor (22×22×20 mm). A surgical resection was performed. Postoperatively, blood pressure normalized, and cardiac function improved (EF increased from 47% to 70% at the 2-month follow-up).
Conclusion: Catecholamine-secreting tumors may induce severe cardiomyopathy even without a hypertension history. Early diagnosis and prompt surgery are critical for cardiac recovery and preventing complications.
Article Details
Keywords
Adrenal tumor, catecholamine, cardiomyopathy, pheochromocytoma
References
[2] Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005 Aug 20;366(9486):665–75.
[3] Mannelli M. Management and Treatment of Pheochromocytomas and Paragangliomas. Annals of the New York Academy of Sciences. 2006;1073(1):405–16.
[4] Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, et al. Pheochromocytoma: current approaches and future directions. Oncologist. 2008 Jul;13(7):779–93.
[5] Alderazi Y, Yeh MW, Robinson BG, Benn DE, Sywak MS, Learoyd DL, et al. Phaeochromocytoma: current concepts. Med J Aust [Internet]. 2005 Aug 15 [cited 2025 May 21];183(4). Available from: https://www.mja.com.au/journal/2005/183/4/phaeochromocytoma-current-concepts
[6] Lenders JWM, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002 Mar 20;287(11):1427–34.
[7] Sawka AM, Jaeschke R, Singh RJ, Young WF. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003 Feb;88(2):553–8.
[8] Sawka AM, Prebtani AP, Thabane L, Gafni A, Levine M, Young WF. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord. 2004 Jun 29;4(1):2.
[9] Eisenhofer G, Pamporaki C, Lenders JWM. Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocr Rev. 2023 Sep 15;44(5):862–909.
[10] Farrugia FA, Martikos G, Tzanetis P, Charalampopoulos A, Misiakos E, Zavras N, et al. Pheochromocytoma, diagnosis and treatment: Review of the literature. Endocr Regul. 2017 Jul 1;51(3):168–81.
[11] Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, et al. Imaging of Pheochromocytoma and Paraganglioma. J Nucl Med. 2021 Aug 1;62(8):1033–42.
[12] Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019 Aug 8;381(6):552–65.
[13] Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci. 2006 Aug;1073:374–82.
[14] Esfandiari NH, Shulkin BL, Bui C, Jaffe CA. Multimodality imaging of malignant pheochromocytoma. Clin Nucl Med. 2006 Dec;31(12):822–5.
[15] Gumbs AA, Gagner M. Laparoscopic adrenalectomy. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):483–99.
[16] Soon PSH, Yeh MW, Delbridge LW, Bambach CP, Sywak MS, Robinson BG, et al. Laparoscopic surgery is safe for large adrenal lesions. Eur J Surg Oncol. 2008 Jan;34(1):67–70.
[17] Recurrent Catecholamine-Induced Cardiomyopathy and Hypertensive Emergencies: A presentation of Pheochromocytoma and Related Concerns - PubMed [Internet]. [cited 2025 May 21]. Available from: https://pubmed.ncbi.nlm.nih.gov/32135056/
[18] Diaz B, Elkbuli A, Ehrhardt JD, McKenney M, Boneva D, Hai S. Pheochromocytoma-related cardiomyopathy presenting as broken heart syndrome: Case report and literature review. Int J Surg Case Rep. 2019;55:7–10.
[19] Santos JRU, Brofferio A, Viana B, Pacak K. Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease? Horm Metab Res. 2019 Jul;51(7):458–69.
[20] Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: A Systematic Analytical Review. - AMiner [Internet]. [cited 2025 May 21]. Available from: https://www.aminer.cn/pub/56d8de9bdabfae2eee036493/acute-and-chronic-pheochromocytoma-induced-cardiomyopathies-different-prognoses-a-systematic-analytical-review?source=zz1
[21] Choi SY, Cho KI, Han YJ, You GI, Kim JH, Heo JH, et al. Impact of Pheochromocytoma on Left Ventricular Hypertrophy and QTc Prolongation: Comparison with Takotsubo Cardiomyopathy. Korean Circ J. 2014 Mar;44(2):89–96.
[22] Martucci VL, Pacak K. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, Management, and Treatment. Curr Probl Cancer. 2014;38(1):7–41.
[23] Mazza A, Armigliato M, Marzola MC, Schiavon L, Montemurro D, Vescovo G, et al. Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrine. 2014 Apr;45(3):469–78.
[24] Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007 Nov;92(11):4069–79.
Similar Articles
- Xuan Hiep Vu, Duy Thang Nguyen, Vu Tu Quyen Doan, Ngoc Thang Duong, Quoc Hung Doan, Surgical outcomes of peripheral vascular trauma in pediatric patients at the Cardiovascular and Thoracic Center, Viet Duc University Hospital , The Vietnam Journal of Cardiovascular and Thoracic Surgery: Vol. 51
You may also start an advanced similarity search for this article.